

Titolo:	A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Recurrent or Advanced Endometrial Cancer Who Have Received Prior Platinum-Based Chemotherapy and Anti-PD-(L)1 Immunotherapy (ASCENT-GYN-01 / ENGOT en-26).
Patologia:	Carcinoma endometriale
Tipo di Studio:	Interventistico con farmaco
Fase:	III
Principali criteri di inclusione:	1. Histologically-confirmed recurrent/persistent endometrial carcinoma or carcinosarcoma 2. Up to 3 prior lines of systemic therapy, including platinum-based CHT and anti-PD-1/PD-L1, either in combination or separately. Neoadjuvant and/or adjuvant CHT is considered one prior line. 3. Radiologically evaluable disease (measurable or non-measurable) 4. Not candidate for curative surgery and/or RT
Key procedure	1. Availability of archival tumor tissue or fresh tumor biopsy for assessment of TROP2 status and other biomarkers.
Sede e contatti	AOU Città della Salute e della Scienza di Torino – PO S. Anna Dott. E. Piovano piovano.elisa@gmail.com